368 trials (keyword fallback)
Infections, Bacterial
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…
Cirrhosis · Hepatic Encephalopathy
Primary: Number of Participants Who Experienced Serious Adverse Events up to Week 6 — 2; 0 Participants
Overt Hepatic Encephalopathy
Primary: Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2 — 36.1; 21.1…
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Alport Syndrome · Kidney Disease
Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants
Infection, Human Immunodeficiency Virus
Primary: Number of Events of ALT Elevation After Baseline, Controlling for APRI Score and Other Variables — 9; 4 events — p=0.02
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) of Entrectinib — 296.140; 213.570; 183.680; 235.990 nmol/L
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Type 2 Diabetes · Dyslipidemia
Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 2058.5; 3872.5; 500.1; 601.2 h*ng/mL
Hepatic Encephalopathy
Primary: Driving Performance — 7.6; 5.5 raw number of driving errors
Hepatic Encephalopathy
Primary: Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event — 78; 15; 158; 49 Participants
Hepatic Encephalopathy · Cirrhosis · Portosystemic Encephalopathy
Primary: Number of Participants With an Improvement of 1 or More in HE Grade at 24 Hours — 21; 13 participants
Cirrhosis · Hepatic Encephalopathy
Primary: Part A: The Rate of AEs and Tolerability of HPN-100 — 11; 9; 7; 4 Subjects